CARMAT raised €40.5 million - set to resume the artificial heart production
Longevity Technology - 21-Apr-2022Aeson could prolong lives of patients awaiting a human heart transplant
Join the club for FREE to access the whole archive and other member benefits.
CEO at Carmat
Stéphane Piat is an acknowledged specialist in the medical device business, particularly in the field of cardiology. He joined Carmat as Chief Executive Officer in September 2016.
Mr Piat started his career at Becton Dickinson European Headquarters as a Market Researcher in 1995. He was appointed European Platform Leader for LocoregionalAnaesthesia five years later. In 2002, he joined Cordis, a Johnson & Johnson company, where he spent five years in several management positions ranging from Business Director France to European Marketing Director for Cardiology. In 2007, he moved to Abbott Vascular as General Manager for mid-size countries, EMEA, and two years later oversaw the integration of Evalve as the company's General Manager EMEA, heading clinical and commercial development of a new interventional cardiology product, Mitraclip. In 2014, he led Global Market Development of the Abbott Vascular Structural Heart Division in San Francisco as Division Vice President.
Mr Piat holds a master's degree in Management Science from IAE Dijon School of Management, and a post-graduate degree in Quantitative Marketing from ESA business school in Grenoble.
Visit website: https://www.carmatsa.com/en/about-carmat/#piat
See also: Carmat - Vision to become the primary alternative to heart transplants with the implementation of our Total Artificial Heart
Details last updated 24-Apr-2022
Aeson could prolong lives of patients awaiting a human heart transplant